- Published on
Diagnostic Tests: Decay-Accelerating Factor (DAF) / CD55–CD59 Assay
Overview
The CD55/CD59 assay—also known as the decay-accelerating factor (DAF) assay—is a laboratory test used to evaluate the presence of GPI-anchored protective proteins on the surface of red blood cells. In paroxysmal nocturnal hemoglobinuria (PNH), a mutation in the PIGA gene prevents the attachment of these proteins, particularly CD55 and CD59, leaving RBCs vulnerable to complement-mediated lysis. Measuring the presence or absence of CD55/CD59 via flow cytometry allows clinicians to directly identify PNH cells.
When This Is the Most Accurate Diagnostic Test
The CD55/CD59 flow cytometry assay is the most accurate and definitive test for diagnosing paroxysmal nocturnal hemoglobinuria. Unlike older screening tests such as the sucrose lysis test or Ham’s test, flow cytometry precisely quantifies the proportion of blood cells lacking complement-regulating proteins. Because it identifies the exact molecular defect, it remains the gold standard for diagnosing PNH.
When to Choose DAF (CD55/CD59) as the Correct Answer
You should select the CD55/CD59 assay when a clinical presentation strongly suggests PNH, especially in cases involving:
Whenever these features cluster together, particularly dark morning urine and thrombosis, the DAF (CD55/CD59) assay is the diagnostic test of choice.
Overview
The CD55/CD59 assay—also known as the decay-accelerating factor (DAF) assay—is a laboratory test used to evaluate the presence of GPI-anchored protective proteins on the surface of red blood cells. In paroxysmal nocturnal hemoglobinuria (PNH), a mutation in the PIGA gene prevents the attachment of these proteins, particularly CD55 and CD59, leaving RBCs vulnerable to complement-mediated lysis. Measuring the presence or absence of CD55/CD59 via flow cytometry allows clinicians to directly identify PNH cells.
When This Is the Most Accurate Diagnostic Test
The CD55/CD59 flow cytometry assay is the most accurate and definitive test for diagnosing paroxysmal nocturnal hemoglobinuria. Unlike older screening tests such as the sucrose lysis test or Ham’s test, flow cytometry precisely quantifies the proportion of blood cells lacking complement-regulating proteins. Because it identifies the exact molecular defect, it remains the gold standard for diagnosing PNH.
When to Choose DAF (CD55/CD59) as the Correct Answer
You should select the CD55/CD59 assay when a clinical presentation strongly suggests PNH, especially in cases involving:
- Intermittent dark urine, often most noticeable in the morning due to overnight complement activation
- Pancytopenia, reflecting bone marrow failure that often accompanies PNH
- Unexplained large-vessel thrombosis, particularly in unusual locations such as hepatic, portal, or cerebral veins
- Hemolysis with a negative Coombs test, consistent with complement-mediated destruction rather than autoimmune hemolysis
Whenever these features cluster together, particularly dark morning urine and thrombosis, the DAF (CD55/CD59) assay is the diagnostic test of choice.
- Published on
Diagnostic Tests: Burr Cells
Overview — What Burr Cells Are
Burr cells, also known as echinocytes, are red blood cells that display numerous short, blunt, and regularly spaced spicules on their surface. Their uniform projections give them a spiky appearance, but unlike spur cells, these projections are consistent and evenly distributed. Burr cells typically reflect alterations in the red cell membrane caused by metabolic abnormalities.
Conditions Associated With Burr Cells
Burr cells appear most commonly in systemic diseases that affect the biochemical environment or membrane composition of red blood cells. They are classically associated with:
While some burr cells may arise from artifact during slide preparation, their presence in an appropriate clinical scenario strongly supports renal or hepatic pathology.
Differentiating Burr Cells From Spur Cells
It is important to distinguish burr cells (echinocytes) from spur cells (acanthocytes) because they indicate different underlying conditions.
Overview — What Burr Cells Are
Burr cells, also known as echinocytes, are red blood cells that display numerous short, blunt, and regularly spaced spicules on their surface. Their uniform projections give them a spiky appearance, but unlike spur cells, these projections are consistent and evenly distributed. Burr cells typically reflect alterations in the red cell membrane caused by metabolic abnormalities.
Conditions Associated With Burr Cells
Burr cells appear most commonly in systemic diseases that affect the biochemical environment or membrane composition of red blood cells. They are classically associated with:
- End-stage renal disease (ESRD)
Uremic toxins disrupt red cell membranes, producing echinocyte formation. - Liver disease
Changes in plasma lipid composition and membrane stability can lead to burr cell development.
While some burr cells may arise from artifact during slide preparation, their presence in an appropriate clinical scenario strongly supports renal or hepatic pathology.
Differentiating Burr Cells From Spur Cells
It is important to distinguish burr cells (echinocytes) from spur cells (acanthocytes) because they indicate different underlying conditions.
- Burr cells (echinocytes):
- Many short, uniform, regularly spaced spicules
- Associated with ESRD and liver disease
- Spur cells (acanthocytes):
- Few, irregular, unevenly spaced spicules
- Seen in severe liver disease, some hereditary spherocytosis, and myelodysplastic syndromes
- Published on
Diagnostic Tests: Anti–Intrinsic Factor Antibodies & Antiparietal Cell Antibodies
Overview
Anti–intrinsic factor (anti-IF) antibodies and antiparietal cell antibodies are highly specific markers used to confirm the diagnosis of pernicious anemia, an autoimmune cause of vitamin B₁₂ deficiency. In pernicious anemia, the immune system attacks either intrinsic factor itself or the gastric parietal cells that produce intrinsic factor and gastric acid. Because vitamin B₁₂ cannot be absorbed without intrinsic factor, autoimmune destruction leads to severe B₁₂ deficiency over time. Anti-intrinsic factor antibodies are nearly 100% specific for pernicious anemia, while antiparietal cell antibodies support the diagnosis but are less specific, as they can also appear in autoimmune gastritis.
When These Antibody Tests Are Used
These antibody tests are ordered after confirming vitamin B₁₂ deficiency, to determine its underlying cause. You should select anti-IF and antiparietal cell antibody testing when evaluating a patient with confirmed B₁₂ deficiency—either through low serum B₁₂ levels or elevated methylmalonic acid—and you need to clarify whether the etiology is pernicious anemia. The clinical scenario usually includes macrocytic anemia, neurologic symptoms, glossitis, or long-standing nutritional deficiency concerns. These antibodies are not used to diagnose B₁₂ deficiency itself, but rather to establish why the deficiency occurred when pernicious anemia is suspected.
Overview
Anti–intrinsic factor (anti-IF) antibodies and antiparietal cell antibodies are highly specific markers used to confirm the diagnosis of pernicious anemia, an autoimmune cause of vitamin B₁₂ deficiency. In pernicious anemia, the immune system attacks either intrinsic factor itself or the gastric parietal cells that produce intrinsic factor and gastric acid. Because vitamin B₁₂ cannot be absorbed without intrinsic factor, autoimmune destruction leads to severe B₁₂ deficiency over time. Anti-intrinsic factor antibodies are nearly 100% specific for pernicious anemia, while antiparietal cell antibodies support the diagnosis but are less specific, as they can also appear in autoimmune gastritis.
When These Antibody Tests Are Used
These antibody tests are ordered after confirming vitamin B₁₂ deficiency, to determine its underlying cause. You should select anti-IF and antiparietal cell antibody testing when evaluating a patient with confirmed B₁₂ deficiency—either through low serum B₁₂ levels or elevated methylmalonic acid—and you need to clarify whether the etiology is pernicious anemia. The clinical scenario usually includes macrocytic anemia, neurologic symptoms, glossitis, or long-standing nutritional deficiency concerns. These antibodies are not used to diagnose B₁₂ deficiency itself, but rather to establish why the deficiency occurred when pernicious anemia is suspected.
- Published on
Diagnostics Tests: Russell’s Viper Venom Clotting Time (RVVT)
Overview — What RVVT Is
Russell’s Viper Venom Clotting Time (RVVT) is a phospholipid-dependent coagulation test used to evaluate abnormalities in the clotting cascade.
The venom directly activates factor X, bypassing most of the intrinsic pathway. Because the test depends on phospholipids, it becomes prolonged when antiphospholipid antibodies interfere with the reaction.
A specialized form, the dilute Russell viper venom test (dRVVT), is used to increase sensitivity for lupus anticoagulant detection.
When RVVT Is Indicated
RVVT is used primarily in the detection of antiphospholipid antibodies, especially the lupus anticoagulant.
You should think of this test when:
RVVT is more specific than traditional PTT testing for diagnosing lupus anticoagulant.
Common Clinical Scenario
A typical clinical vignette that points toward lupus anticoagulant and therefore RVVT includes:
Overview — What RVVT Is
Russell’s Viper Venom Clotting Time (RVVT) is a phospholipid-dependent coagulation test used to evaluate abnormalities in the clotting cascade.
The venom directly activates factor X, bypassing most of the intrinsic pathway. Because the test depends on phospholipids, it becomes prolonged when antiphospholipid antibodies interfere with the reaction.
A specialized form, the dilute Russell viper venom test (dRVVT), is used to increase sensitivity for lupus anticoagulant detection.
When RVVT Is Indicated
RVVT is used primarily in the detection of antiphospholipid antibodies, especially the lupus anticoagulant.
You should think of this test when:
- A patient has a prolonged PTT
- The PTT does not correct with a mixing study (suggesting an inhibitor rather than a factor deficiency)
- You need confirmation that the inhibitor is specifically a lupus anticoagulant
RVVT is more specific than traditional PTT testing for diagnosing lupus anticoagulant.
Common Clinical Scenario
A typical clinical vignette that points toward lupus anticoagulant and therefore RVVT includes:
- A woman, often of childbearing age
- With or without known systemic lupus erythematosus (SLE)
- Recurrent spontaneous abortions (classic high-yield clue)
- History of unexplained venous or arterial thrombosis, such as:
- Deep vein thrombosis
- Pulmonary embolism
- Stroke in a young patient
- Or delivering an infant with congenital heart block (neonatal lupus can occur from anti-Ro/SSA, often coexisting with antiphospholipid antibodies)
- Published on
Diagnostic Tests: Ristocetin Cofactor Assay
Overview — What This Test Is
The Ristocetin Cofactor Assay is a laboratory test that evaluates the functional activity of von Willebrand factor (VWF).
Ristocetin acts as a surrogate for the endothelial surface, promoting VWF-mediated platelet agglutination. When VWF is present and functioning normally, platelets will clump in response to ristocetin.
This assay, together with a VWF antigen level, is considered one of the most accurate tests for diagnosing von Willebrand disease (vWD).
When This Is the Correct Answer
Choose the Ristocetin Cofactor Assay when a patient presents with:
This pattern suggests qualitative VWF defects, particularly Type 2 von Willebrand disease, where VWF quantity may be normal but function is impaired.
The ristocetin assay detects impaired VWF-mediated platelet adhesion, helping distinguish between quantitative and qualitative defects.
Overview — What This Test Is
The Ristocetin Cofactor Assay is a laboratory test that evaluates the functional activity of von Willebrand factor (VWF).
Ristocetin acts as a surrogate for the endothelial surface, promoting VWF-mediated platelet agglutination. When VWF is present and functioning normally, platelets will clump in response to ristocetin.
This assay, together with a VWF antigen level, is considered one of the most accurate tests for diagnosing von Willebrand disease (vWD).
When This Is the Correct Answer
Choose the Ristocetin Cofactor Assay when a patient presents with:
- Platelet-type bleeding, such as:
- Epistaxis
- Petechiae
- Purpura
- Gum bleeding or gingival bleeding
- Normal platelet count
- Normal VWF level, but clinical suspicion for vWD remains
(e.g., VWF is present but non-functional)
This pattern suggests qualitative VWF defects, particularly Type 2 von Willebrand disease, where VWF quantity may be normal but function is impaired.
The ristocetin assay detects impaired VWF-mediated platelet adhesion, helping distinguish between quantitative and qualitative defects.
- Published on
Diagnostic Tests: Bleeding Time
Overview
Bleeding time is a traditional test that evaluates the function of platelets, specifically their ability to adhere to damaged endothelium and form the initial platelet plug. It does not measure coagulation factors and should not be used when the platelet count is low, because anyone with thrombocytopenia will automatically have a prolonged bleeding time. Instead, bleeding time is helpful only when platelet number is normal but platelet function is suspected to be abnormal.
How the Test Is Performed
To perform the bleeding time test, a blood pressure cuff is inflated to 40 mmHg to standardize vascular pressure and engorge capillaries. Small standardized cuts are then made in the skin, and the time required for bleeding to stop is measured. A prolonged bleeding time indicates impaired platelet adhesion or aggregation.
When Bleeding Time Is the Correct Answer
Bleeding time is chosen when a patient has abnormal bleeding suggestive of a platelet disorder, but the platelet count is normal. These clinical scenarios involve qualitative platelet dysfunction, not a quantitative deficiency. Classic examples include:
These conditions impair platelet function even though platelet numbers remain normal. Thus, a prolonged bleeding time supports the suspicion of a functional platelet abnormality.
Most Accurate Tests
Although bleeding time can suggest platelet dysfunction, it is not the most accurate test for diagnosing specific disorders. More precise evaluations include:
These tests provide definitive diagnostic information for platelet-type bleeding disorders, particularly von Willebrand disease.
Overview
Bleeding time is a traditional test that evaluates the function of platelets, specifically their ability to adhere to damaged endothelium and form the initial platelet plug. It does not measure coagulation factors and should not be used when the platelet count is low, because anyone with thrombocytopenia will automatically have a prolonged bleeding time. Instead, bleeding time is helpful only when platelet number is normal but platelet function is suspected to be abnormal.
How the Test Is Performed
To perform the bleeding time test, a blood pressure cuff is inflated to 40 mmHg to standardize vascular pressure and engorge capillaries. Small standardized cuts are then made in the skin, and the time required for bleeding to stop is measured. A prolonged bleeding time indicates impaired platelet adhesion or aggregation.
When Bleeding Time Is the Correct Answer
Bleeding time is chosen when a patient has abnormal bleeding suggestive of a platelet disorder, but the platelet count is normal. These clinical scenarios involve qualitative platelet dysfunction, not a quantitative deficiency. Classic examples include:
- Von Willebrand disease
- Uremia-induced platelet dysfunction
These conditions impair platelet function even though platelet numbers remain normal. Thus, a prolonged bleeding time supports the suspicion of a functional platelet abnormality.
Most Accurate Tests
Although bleeding time can suggest platelet dysfunction, it is not the most accurate test for diagnosing specific disorders. More precise evaluations include:
- Von Willebrand factor level
- Ristocetin cofactor assay (tests VWF function)
- In vitro platelet aggregation studies (directly assess platelet function)
These tests provide definitive diagnostic information for platelet-type bleeding disorders, particularly von Willebrand disease.
- Published on
Diagnostic Tests: Serum Protein Electrophoresis (SPEP)
Overview — What SPEP Is?
Serum protein electrophoresis (SPEP) is a laboratory test that separates and quantifies the major protein components of the blood. By applying an electric current to serum, proteins migrate based on their size and charge, producing a pattern that distinguishes:
- Albumin
- α1, α2, β, and γ globulin fractions
- Immunoglobulins (IgG, IgA, IgM, etc.)
This allows clinicians to identify abnormal elevations—especially monoclonal spikes (“M-spikes”) that suggest plasma cell disorders.
When SPEP Is the Correct Answer
Choose SPEP when evaluating:
- Elevated total serum protein
- Unexplained anemia, especially with rouleaux formation
- Bone pain or lytic lesions on X-ray
- Renal failure of unclear origin
- Symptoms suggestive of plasma cell dyscrasias (fatigue, weight loss, recurrent infections)
SPEP is the best initial test to diagnose multiple myeloma, particularly when:
- X-rays for lytic lesions have already been performed
- Or when imaging is not an available answer choice
Most Common Reason for an Abnormal SPEP
The most common cause of an abnormal SPEP—particularly a monoclonal spike—is:
Monoclonal Gammopathy of Unknown/Undetermined Significance (MGUS)
MGUS is far more common than multiple myeloma and is often asymptomatic, although it requires monitoring due to its risk of progression.
Most Accurate Diagnostic Test
For confirming an IgG monoclonal abnormality detected on SPEP, the most accurate test is:
Bone Marrow Biopsy
Findings diagnostic of multiple myeloma include:
- >10% clonal plasma cells
- Evidence of organ damage (CRAB criteria: hyperCalcemia, Renal failure, Anemia, Bone lesions)
If you’d like, I can produce a quick comparison table: SPEP vs. UPEP vs. Immunofixation, or a high-yield myeloma diagnostic algorithm.
- Published on
Diagnostic Tests: Sucrose Lysis Test
Overview — What This Test Is
The sucrose lysis test is a screening test for paroxysmal nocturnal hemoglobinuria (PNH).
In this test, the patient’s red blood cells are placed in a sucrose-containing solution, which promotes complement activation. PNH RBCs are unusually sensitive to complement-mediated destruction, so the presence of hemolysis in this solution suggests PNH.
The mechanism:
When to Answer “Sucrose Lysis Test”
Choose the sucrose lysis test in a clinical scenario that describes the classic features of PNH, such as:
When these features appear together, the sucrose lysis test is the classic screening test.
Most Accurate Diagnostic Test
The most accurate and modern diagnostic test for PNH is:
Flow Cytometry for CD55 and CD59 Deficiency
Flow cytometry is the gold standard because it directly demonstrates the absence of these protective markers on RBCs and WBCs.
Overview — What This Test Is
The sucrose lysis test is a screening test for paroxysmal nocturnal hemoglobinuria (PNH).
In this test, the patient’s red blood cells are placed in a sucrose-containing solution, which promotes complement activation. PNH RBCs are unusually sensitive to complement-mediated destruction, so the presence of hemolysis in this solution suggests PNH.
The mechanism:
- PNH cells lack protective surface proteins (CD55, CD59) that normally prevent complement-mediated lysis.
- Sucrose enhances complement binding → RBC destruction → hemolysis detected.
When to Answer “Sucrose Lysis Test”
Choose the sucrose lysis test in a clinical scenario that describes the classic features of PNH, such as:
- Dark urine in the morning (from overnight hemoglobinuria)
- Episodic hemolysis
- Pancytopenia
- Venous thrombosis, especially in unusual sites such as hepatic, portal, or cerebral veins
- Negative Coombs test (helps distinguish PNH from autoimmune hemolysis)
When these features appear together, the sucrose lysis test is the classic screening test.
Most Accurate Diagnostic Test
The most accurate and modern diagnostic test for PNH is:
Flow Cytometry for CD55 and CD59 Deficiency
- These proteins are also called decay-accelerating factor (DAF) and membrane inhibitor of reactive lysis (MIRL).
- PNH cells are missing CD55 and CD59 due to a mutation in the PIGA gene affecting the GPI anchor that normally attaches these protective proteins to the cell surface.
Flow cytometry is the gold standard because it directly demonstrates the absence of these protective markers on RBCs and WBCs.
- Published on
Diagnostic Tests: Schilling Test
Overview — Clinical Conditions for Which the Schilling Test Is Used
The Schilling test is a historical diagnostic test used to determine the cause of vitamin B₁₂ (cobalamin) deficiency.
Although rarely used today, it is a classic board-style question.
The most common cause of B₁₂ deficiency is pernicious anemia, which results from autoantibodies against intrinsic factor (IF) or against parietal cells that produce IF.
The Schilling test helps differentiate:
How the Schilling Test Is Performed
The Schilling test is performed in stages:
Stage 1
Stage 2
The test is repeated, this time with oral intrinsic factor added to the radiolabeled B₁₂.
Interpretation:
Schilling’s test is rarely the correct answer today, but in board-style questions you choose it when:
In other words, use the Schilling test only when the cause of B₁₂ deficiency is unknown and pernicious anemia has not been confirmed by simpler tests.
If you’d like, I can provide a comparison of B₁₂ deficiency vs. folate deficiency, or a simple diagnostic algorithm for evaluating macrocytic anemia.
Overview — Clinical Conditions for Which the Schilling Test Is Used
The Schilling test is a historical diagnostic test used to determine the cause of vitamin B₁₂ (cobalamin) deficiency.
Although rarely used today, it is a classic board-style question.
The most common cause of B₁₂ deficiency is pernicious anemia, which results from autoantibodies against intrinsic factor (IF) or against parietal cells that produce IF.
The Schilling test helps differentiate:
- Pernicious anemia (intrinsic factor deficiency)
from - Intestinal malabsorption of B₁₂
- Other causes of poor cobalamin absorption
How the Schilling Test Is Performed
The Schilling test is performed in stages:
Stage 1
- Oral dose of radiolabeled vitamin B₁₂ (cyanocobalamin) is given.
- Intramuscular injection of unlabeled B₁₂ is given 1 hour later to saturate binding sites and ensure radiolabeled B₁₂ is excreted in the urine if absorbed normally.
- Urine is collected for 24 hours to measure the percentage of radiolabeled B₁₂ excreted.
- Low urinary excretion → indicates poor absorption of B₁₂
Stage 2
The test is repeated, this time with oral intrinsic factor added to the radiolabeled B₁₂.
Interpretation:
- Urinary excretion normalizes → Pernicious anemia (lack of intrinsic factor).
- Urinary excretion remains low → intestinal malabsorption (e.g., ileal disease, bacterial overgrowth, pancreatic insufficiency).
Schilling’s test is rarely the correct answer today, but in board-style questions you choose it when:
- The patient clearly has vitamin B₁₂ deficiency, and
- Tests for intrinsic factor antibodies and parietal cell antibodies are negative, and
- The etiology is still unclear, or
- The antibody tests are not available among the answer choices
In other words, use the Schilling test only when the cause of B₁₂ deficiency is unknown and pernicious anemia has not been confirmed by simpler tests.
If you’d like, I can provide a comparison of B₁₂ deficiency vs. folate deficiency, or a simple diagnostic algorithm for evaluating macrocytic anemia.
- Published on
Diagnostic Tests: Hairy Cell Leukemia (Blood Smear Findings)
Overview — What the Blood Smear Shows
The blood smear displays lymphoid cells with characteristic cytoplasmic projections, known as “hairy cells.” These projections give the cells a fuzzy or “hairy” appearance, which is the classic morphologic hallmark of hairy cell leukemia (HCL). This is a rare, chronic B-cell lymphoproliferative disorder.
Clinical Scenario — When to Suspect and Answer Hairy Cell Leukemia
Hairy cell leukemia should be strongly suspected when the clinical presentation includes:
This combination—middle-aged patient, massive splenomegaly, pancytopenia, and characteristic smear findings—points to hairy cell leukemia.
Most Accurate Diagnostic Test
The most accurate test for confirming hairy cell leukemia is:
Tartrate-Resistant Acid Phosphatase (TRAP) positivity
(Modern practice also uses flow cytometry markers such as CD11c, CD25, CD103, and detection of BRAF V600E mutation, but TRAP is the classic board-test answer.)
If you’d like, I can also create a rapid diagnostic table comparing hairy cell leukemia with CLL, AML, and other pancytopenia causes.
Clinical Scenario — When to Suspect and Answer Hairy Cell Leukemia
Hairy cell leukemia should be strongly suspected when the clinical presentation includes:
This combination—middle-aged patient, massive splenomegaly, pancytopenia, and characteristic smear findings—points to hairy cell leukemia.
Overview — What the Blood Smear Shows
The blood smear displays lymphoid cells with characteristic cytoplasmic projections, known as “hairy cells.” These projections give the cells a fuzzy or “hairy” appearance, which is the classic morphologic hallmark of hairy cell leukemia (HCL). This is a rare, chronic B-cell lymphoproliferative disorder.
Clinical Scenario — When to Suspect and Answer Hairy Cell Leukemia
Hairy cell leukemia should be strongly suspected when the clinical presentation includes:
- A middle-aged man (most common demographic)
- Gradual onset of fatigue, weakness, or recurrent infections
- Massive splenomegaly, often the dominant physical finding
- Hepatomegaly (present in about 50% of patients)
- Pancytopenia, which is the hallmark laboratory abnormality
- Particularly monocytopenia
- Bone marrow often becomes fibrotic and difficult to aspirate (“dry tap”)
This combination—middle-aged patient, massive splenomegaly, pancytopenia, and characteristic smear findings—points to hairy cell leukemia.
Most Accurate Diagnostic Test
The most accurate test for confirming hairy cell leukemia is:
Tartrate-Resistant Acid Phosphatase (TRAP) positivity
- Performed on a bone marrow biopsy
- Hairy cells show strong acid phosphatase activity that remains positive even in the presence of tartrate, distinguishing them from other leukemic cells.
(Modern practice also uses flow cytometry markers such as CD11c, CD25, CD103, and detection of BRAF V600E mutation, but TRAP is the classic board-test answer.)
If you’d like, I can also create a rapid diagnostic table comparing hairy cell leukemia with CLL, AML, and other pancytopenia causes.
Clinical Scenario — When to Suspect and Answer Hairy Cell Leukemia
Hairy cell leukemia should be strongly suspected when the clinical presentation includes:
- A middle-aged man (most common demographic)
- Gradual onset of fatigue, weakness, or recurrent infections
- Massive splenomegaly, often the dominant physical finding
- Hepatomegaly (present in about 50% of patients)
- Pancytopenia, which is the hallmark laboratory abnormality
- Particularly monocytopenia
- Bone marrow often becomes fibrotic and difficult to aspirate (“dry tap”)
This combination—middle-aged patient, massive splenomegaly, pancytopenia, and characteristic smear findings—points to hairy cell leukemia.
